See more : Global Care Capital Inc. (RSCZF) Income Statement Analysis – Financial Results
Complete financial analysis of Kraig Biocraft Laboratories, Inc. (KBLB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kraig Biocraft Laboratories, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- NCR Corporation 5.5% PFD CNV A (NCRRP) Income Statement Analysis – Financial Results
- Asia Aviation Public Company Limited (AAV-R.BK) Income Statement Analysis – Financial Results
- Aozora Bank, Ltd. (8304.T) Income Statement Analysis – Financial Results
- PT Kapuas Prima Coal Tbk (ZINC.JK) Income Statement Analysis – Financial Results
- Engie Energia Chile S.A. (ECL.SN) Income Statement Analysis – Financial Results
Kraig Biocraft Laboratories, Inc. (KBLB)
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.62K | 97.32K | 31.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 27.62K | 28.10K | 3.68B | 13.09B | 14.79B | 11.52B | 10.56B | 16.97K | 15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.62K | -28.10K | -3.68B | -13.09B | -14.79B | -11.52B | -10.56B | 14.88K | -15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,868,283.05% | -10,850,924.48% | 46.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 237.87K | 176.43K | 197.75K | 88.47K | 223.05K | 148.07K | 258.89K | 397.14K | 432.01K | 439.54K | 489.43K | 465.29K | 250.60K | 141.31K | 69.80K | 33.08K | 177.02K | 164.91K |
| General & Administrative | 1.58M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 320.00K | 300.00K | 370.00K |
| Selling & Marketing | 797.41K | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.01K | -13.34K | -5.25K |
| SG&A | 2.38M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 312.99K | 286.66K | 364.75K |
| Other Expenses | 0.00 | 779.74B | 734.43B | 516.33B | 627.20B | -1.00 | 2.00 | -4.00 | -2.00 | -4.00 | -5.19M | 3.00K | 598.00 | 93.91K | 27.20K | 12.65K | 6.21K | -5.09K |
| Operating Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Cost & Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Interest Income | 0.00 | 1.72K | 5.36K | 386.62 | 6.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.00 | 192.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 375.10K | 609.13K | 660.42K | 386.62K | 294.35K | 228.95K | 177.11K | 139.43K | 101.55K | 69.28K | 0.00 | 45.71K | 0.00 | 52.38K | 41.81K | 7.24K | 122.00 | 654.00 |
| Depreciation & Amortization | 27.62K | 28.10K | 26.14K | 28.07K | 30.78K | 26.63K | 20.29K | 16.97K | 15.42K | 7.16K | 5.89K | 5.58K | 5.37K | 453.00 | 27.40K | -2.78K | 0.00 | 0.00 |
| EBITDA | -2.59M | -2.09M | -2.73M | -4.56M | -2.58M | -913.39K | -2.14M | -2.92M | -2.04M | -1.83M | -2.22M | -1.55M | -1.29M | -1.64M | -2.72M | -355.65K | -472.86K | -529.67K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -232.39% | -2,194.56% | -9,192.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.61M | -2.12M | -2.76M | -4.53M | -2.62M | -959.95K | -2.16M | -2.95M | -2.05M | -1.83M | -2.28M | -1.16M | -1.30M | -1.29M | -524.71K | -355.65K | -472.86K | -529.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -239.02% | -2,215.41% | -9,246.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -414.99K | -1.72M | -5.29M | -437.13K | -287.98K | -209.03K | -177.11K | -128.24K | -79.25K | -38.63K | -5.25M | -1.60M | 2.10K | -589.06K | -907.38K | -4.46K | -122.00 | -333.00 |
| Income Before Tax | -3.03M | -3.84M | -8.05M | -4.97M | -2.91M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.72M | 660.42K | 386.62K | 294.35K | 19.92K | 0.00 | 139.43K | 101.55K | 69.28K | 0.00 | 48.71K | 0.00 | 52.38K | 41.81K | 7.24K | 0.00 | 321.00 |
| Net Income | -3.03M | -5.56M | -8.71M | -5.36M | -3.20M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
| Weighted Avg Shares Out (Dil) | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
Kraig Biocraft Laboratories Announces Successful Launch of Spring Production Trials in Southeast Asia for Spider Silk
ANN ARBOR, Mich., April 15, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that the spring production trials for the new BAM-1 hybrid have begun and are well on track to...
Kraig Biocraft Laboratories Signs Landmark Agreement in Vietnam's Silk Production Capital
ANN ARBOR, Mich., April 08, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has signed a landmark agreement with the Vietnam Sericulture Association ("VSA").
Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spider Silk from Waste Plastics
ANN ARBOR, Mich., March 28, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute ("RPI").
Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials
Dr. Nirmal Kumar, a globally recognized sericulture expert, will join Kraig Labs (OTCQB:KBLB) Senior Management in Vietnam to supervise launch of the BAM-1
Kraig Biocraft Laboratories Senior Management travels to Vietnam for Launch of Spring Trials
ANN ARBOR, Mich., March 12, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), announces today that senior management members will travel to Vietnam this week to oversee the launch of the spring production...
Kraig Biocraft Laboratories Preparing Additional Business Investment License to Advance its Business Operations
Kraig Labs (OTCQB:KBLB) expects to submit its second business investment application in Vietnam as part of the planned expansion of its business operations
Kraig Biocraft Laboratories Establishes Homozygosity and Confirms BAM 1 Hybrid Optimized Ahead of Spring Production Trials
ANN ARBOR, Mich., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), announces that it has achieved homozygosity for the spider silk gene in both of the parental strains for its new...
Kraig Biocraft Laboratories Announces New Premium Spider Silk and Pima Cotton Composite Yarn
ANN ARBOR, Mich., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or "the Company"), announces the creation of its first premium yarn combining its recombinant spider silk with Pima Cotton.
Kraig Biocraft Laboratories Announces New Spider Silk Production Facility in Vietnam's Silk Capital
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces it has now taken possession of its new recombinant spider silk production center in Lam Dong Province, Vietnam.
Kraig Biocraft Laboratories Announces Creation of Production Ready Spider Silk Hybrid: BAM 1
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), announces the successful creation of a new recombinant spider silk hybrid.
Source: https://incomestatements.info
Category: Stock Reports